- Home
- CGEM vs INNV Comparison
CGEM vs INNV Comparison
Compare CGEM & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- INNV
- Stock Information
- Founded
- CGEM 2016
- INNV 2007
- Country
- CGEM United States
- INNV United States
- Employees
- CGEM N/A
- INNV N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- INNV Medical/Nursing Services
- Sector
- CGEM Health Care
- INNV Health Care
- Exchange
- CGEM Nasdaq
- INNV Nasdaq
- Market Cap
- CGEM 437.2M
- INNV 485.4M
- IPO Year
- CGEM 2021
- INNV 2021
- Fundamental
- Price
- CGEM $8.49
- INNV $5.08
- Analyst Decision
- CGEM Strong Buy
- INNV Sell
- Analyst Count
- CGEM 7
- INNV 2
- Target Price
- CGEM $26.00
- INNV $5.00
- AVG Volume (30 Days)
- CGEM 1.5M
- INNV 67.2K
- Earning Date
- CGEM 11-07-2025
- INNV 11-04-2025
- Dividend Yield
- CGEM N/A
- INNV N/A
- EPS Growth
- CGEM N/A
- INNV N/A
- EPS
- CGEM N/A
- INNV N/A
- Revenue
- CGEM N/A
- INNV $853,699,000.00
- Revenue This Year
- CGEM N/A
- INNV $10.66
- Revenue Next Year
- CGEM N/A
- INNV $9.67
- P/E Ratio
- CGEM N/A
- INNV N/A
- Revenue Growth
- CGEM N/A
- INNV 11.76
- 52 Week Low
- CGEM $5.68
- INNV $2.60
- 52 Week High
- CGEM $17.50
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- CGEM 62.54
- INNV 48.87
- Support Level
- CGEM $7.69
- INNV $4.87
- Resistance Level
- CGEM $8.69
- INNV $5.40
- Average True Range (ATR)
- CGEM 0.65
- INNV 0.44
- MACD
- CGEM 0.06
- INNV -0.10
- Stochastic Oscillator
- CGEM 72.76
- INNV 17.82
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.